A validated in-house assay for HIV drug resistance mutation surveillance from dried blood spot specimens

被引:1
|
作者
Neufeld, Bronwyn [1 ]
Munyuza, Chantal [1 ]
Reimer, Alexandria [1 ]
Capina, Rupert [1 ]
Lee, Emma R. [1 ]
Becker, Marissa [2 ,3 ]
Sandstrom, Paul [1 ]
Ji, Hezhao [1 ,2 ]
Cholette, Francois
机构
[1] Natl Sexually Transmitted & Blood Borne Infect Lab, Natl Microbiol Lab, Publ Hlth Agcy Canada, JC Wilt Infect Dis Res Ctr, 745 Logan Ave, Winnipeg, MB R3E 3L5, Canada
[2] Univ Manitoba, Max Rady Coll Med, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada
[3] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada
基金
美国国家卫生研究院;
关键词
HIV; Drug resistance; Dried blood spots; Surveillance; GENOTYPING ASSAY; VIRAL LOAD; ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; FIELD-EVALUATION; SUBTYPE-B; GENOMES; AFRICA; PLASMA; PCR;
D O I
10.1016/j.jviromet.2024.114939
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Despite increasing scale-up of antiretroviral therapy (ART) coverage, challenges related to adherence and HIV drug resistance (HIVDR) remain. The high cost of HIVDR surveillance is a persistent challenge with implementation in resource-constrained settings. Dried blood spot (DBS) specimens have been demonstrated to be a feasible alternative to plasma or serum for HIVDR genotyping and are more suitable for lower resource settings. There is a need for affordable HIVDR genotyping assays which can amplify HIV-1 sequences from DBS specimens, particularly those with low viral loads, at a low cost. Here, we present an in-house assay capable of reliably amplifying HIV-1 protease and partial reverse transcriptase genes from DBS specimens, which covers the complete World Health Organization 2009 list of drug resistance mutations under surveillance. DBS specimens were prepared using whole blood spiked with HIV-1 at concentrations of 10,000, 5000, 1000, and 500 copies/mL (n=30 for each concentration). Specimens were tested in triplicate. A two-step approach was used consisting of cDNA synthesis followed by nested PCR. The limit of detection of the assay was calculated to be approximately 5000 (95 % CI: 3200-10,700) copies/mL for the protease gene and 3600 (95 % CI: 2200-10,000) copies/mL for reverse transcriptase. The assay was observed to be most sensitive with higher viral load specimens (97.8 % [95 % CI: 92.2-99.7]) for both protease and reverse transcriptase at 10,000 copies/mL with performance decreasing with the use of specimens with lower viral loads (46.7 % [36.1-57.5] and 60.0 % [49.1-70.2] at 500 copies/mL for protease and reverse transcriptase, respectively). Ultimately, this assay presents a promising opportunity for use in resource-constrained settings. Future work should involve validation under field conditions including sub-optimal storage conditions and preparation of DBS with fingerprick blood in order to accurately reflect real-world collection scenarios.
引用
收藏
页数:6
相关论文
共 50 条
  • [11] The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy
    Salimo, Anna T.
    Ledwaba, Johanna
    Coovadia, Ashraf
    Abrams, Elaine J.
    Technau, Karl-Guenter
    Kuhn, Louise
    Morris, Lynn
    Hunt, Gillian M.
    JOURNAL OF VIROLOGICAL METHODS, 2015, 223 : 30 - 32
  • [12] HIV-1 drug resistance surveillance using dried whole blood spots
    Bertagnolio, Silvia
    Soto-Ramirez, Luis
    Pilon, Richard
    Rodriguez, Roberto
    Viveros, Monica
    Fuentes, Luis
    Harrigan, P. Richard
    Mo, Theresa
    Sutherland, Don
    Sandstrom, Paul
    ANTIVIRAL THERAPY, 2007, 12 (01) : 107 - 113
  • [13] Pooled pyrosequencing of dried blood spot specimens is an efficient and cost-effective method of conducting HIV drug resistance threshold surveys
    Ji, H.
    Li, Y.
    Graham, M.
    Liang, B.
    Pilon, R.
    Tyson, S.
    Peters, G.
    Tyler, S.
    Merks, H.
    Sandstrom, P.
    Brooks, J.
    ANTIVIRAL THERAPY, 2010, 15 : A91 - A91
  • [14] Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance
    Buckton, Andrew J.
    Bissett, Sara L.
    Myers, Richard E.
    Beddows, Simon
    Edwards, Simon
    Cane, Patricia A.
    Pillay, Deenan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (06) : 1191 - 1198
  • [15] Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens
    Marconi, A.
    Balestrieri, M.
    Comastri, G.
    Pulvirenti, F. R.
    Gennari, W.
    Tagliazucchi, S.
    Pecorari, M.
    Borghi, V.
    Marri, D.
    Zazzi, M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 (01) : 93 - 97
  • [16] Surveillance of Transmitted HIV Drug Resistance Using Matched Plasma and Dried Blood Spot Specimens From Voluntary Counseling and Testing Sites in Ho Chi Minh City, Vietnam, 2007-2008
    Duc, Nguyen Bui
    Hien, Bui Thu
    Wagar, Nick
    Tran Hong Tram
    Le Truong Giang
    Yang, Chunfu
    Wolfe, Mitchell I.
    Nguyen Tran Hien
    Nguyen Anh Tuan
    CLINICAL INFECTIOUS DISEASES, 2012, 54 : S343 - S347
  • [17] Performance of an in-house multiplex PCR assay for HIV-1 drug resistance testing - A cheaper alternative
    Fortuin, Tumelo L.
    Nkone, Paballo
    Glass, Allison
    Viana, Raquel
    Moeng, Keitumetse
    Loubser, Shayne
    Tiemessen, Caroline T.
    Mayaphi, Simnikiwe H.
    JOURNAL OF VIROLOGICAL METHODS, 2024, 330
  • [18] An in-house HIV genotyping assay for the detection of drug resistance mutations in Southeast Asian patients infected with HIV-1
    Lee, Chun Kiat
    Lee, Hong Kai
    Loh, Tze Ping
    Sethi, Sunil Kumar
    Koay, Evelyn Siew-Chuan
    Tang, Julian Wei-Tze
    JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (03) : 394 - 401
  • [19] Performance of 'Xpert® HIV-1 Qual assay' for diagnosis of HIV-1 infection using Dried Blood Spot specimens
    Gadhe, S.
    Mourya, N.
    Goel, N.
    Kurle, S.
    HIV MEDICINE, 2019, 20 : 311 - 311
  • [20] Application of a broadly sensitive genotyping assay using dried blood spots for surveillance of HIV-1 drug resistance in PEPFAR countries
    McNulty, A.
    Diallo, K.
    Zhang, J.
    Kassim, S.
    Bennett, D.
    Aberle-Gasse, J.
    Kibuka, T.
    Nkengasong, J. N.
    Yang, C.
    ANTIVIRAL THERAPY, 2007, 12 : S59 - S59